P/B
3,3
United Therapeutics
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
$21.2B
Market Cap • 9/18/2026
1996
(30 years)
Founded
1999
(27 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
6,7
P/EBITDA
14,2
P/OCF
12,6
P/FCF
19,4
P/E
17,7
BVPS
136,5
EPS
28
Market Cap
Market Cap
21,2B
EV
18,6B
EV/Revenue
5,9
EV/EBITDA
12,4
EV/EBIT
13,2
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
10,2%
Total Yield
10,2%
Payout
0%
Retained Earnings
9,2B
Profitability
Gross Margin
86,1%
EBITDA Margin
47,3%
EBIT Margin
44,4%
Net Margin
41,6%
D&A/EBITDA
0%
R&D/Revenue
17,5%
Capex/Revenue
18,8%
Capex/D&A
647,2%
Capex/OCF
35,1%
SBC/OCF
9,2%
% PPE
26,7%
% Goodwill
1,6%
ROE
19,3%
ROIC
28,2%
Growth
CAGR Revenue 5Y
14,7%
CAGR Op. Income 5Y
25,9%
CAGR Net Income 5Y
22,7%
CAGR EPS 5Y
22,1%
CAGR OCF 5Y
22,3%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
5,7
Quick Ratio
4,9
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!